Medicus Pharma submits Rare Pediatric Disease application for SkinJect
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2026
0mins
Medicus Pharma Ltd's stock surged by 29.03% as it crossed above the 5-day SMA, reflecting positive investor sentiment following significant regulatory news.
The company has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect®, aimed at treating Gorlin Syndrome. This submission follows promising Phase 2 clinical trial results, which showed a 64% clinical clearance rate for the 200ug D-MNA treatment arm, indicating SkinJect®'s potential as a non-surgical treatment for basal cell carcinoma. The market opportunity for this treatment is substantial, with an estimated U.S. patient population of 6,000 to 12,000, potentially tapping into a $2 billion market.
This regulatory milestone not only enhances Medicus Pharma's competitive position but also signals a commitment to addressing significant unmet medical needs, which could attract further investment and support for the company's future endeavors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDCX
Wall Street analysts forecast MDCX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.400
Low
12.00
Averages
12.00
High
12.00
Current: 0.400
Low
12.00
Averages
12.00
High
12.00
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medicus Pharma to Participate in 2026 Bio International Conference
- Clinical Progress Update: Medicus Pharma will showcase clinical data for SkinJect® at the 2026 Bio International Conference, particularly highlighting a 55% histological clearance and 64% clinical clearance rate from the SKNJCT-003 study, indicating the therapy's potential in treating basal cell carcinoma and possibly opening new market opportunities for the company.
- FDA Interaction Progress: The company is actively engaging with the U.S. FDA in preparation for the SKNJCT-003 End-of-Phase 2 meeting and is applying for Rare Pediatric Disease and Orphan Drug Designations, which, if granted, could provide market exclusivity and expedited review benefits for SkinJect®.
- New Study Launch: The PRECISION-E2 Phase 2a clinical trial for Teverelix® has been initiated in the UAE, aimed at optimizing treatment options for endometriosis patients through genomic profiling, potentially establishing a new framework for precision medicine in women's health.
- Strategic Partnership Opportunities: Medicus focuses on de-risking through Phase 2 trials to generate decision-grade data that attracts pharmaceutical partners, enhancing the company's competitiveness and appeal in the biotechnology sector.
See More
Medicus Pharma Submits Rare Pediatric Disease Designation for SkinJect
- Regulatory Submission: Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect, targeting basal cell carcinoma treatment in Gorlin Syndrome patients, indicating the company's strategic focus on addressing significant unmet medical needs.
- Clinical Trial Results: The recent Phase 2 study of SkinJect demonstrated a 64% clinical clearance rate and a 55% histological clearance rate, showcasing its efficacy in treating basal cell carcinoma while maintaining a favorable safety and tolerability profile.
- Market Potential: Gorlin Syndrome affects an estimated 6,000 to 12,000 individuals in the U.S., and Medicus Pharma anticipates that the RPDD submission will bolster its regulatory strategy and facilitate the development of non-surgical treatment options.
- Stock Price Reaction: Medicus shares closed at $0.32, down 5.24%, reflecting market caution regarding the progress of its drug development, which may impact future funding and investor confidence.
See More
Medicus Pharma Submits Rare Pediatric Disease Application
- Rare Disease Application: Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect®, aimed at providing new treatment options for patients with Gorlin Syndrome, marking a significant milestone in advancing SkinJect® through the regulatory process.
- Clinical Trial Results: The recently completed Phase 2 study showed that the 200ug D-MNA treatment arm of SkinJect® achieved a 64% clinical clearance rate and a 55% complete response rate, indicating its potential as an important non-surgical treatment option for basal cell carcinoma.
- Market Opportunity: Gorlin Syndrome affects approximately 1 in 30,000 to 1 in 60,000 individuals globally, with an estimated U.S. patient population of 6,000 to 12,000, positioning SkinJect® to address this significant unmet medical need and tap into a market opportunity of around $2 billion.
- Regulatory Strategy: If granted Rare Pediatric Disease Designation, SkinJect® may qualify for a Priority Review Voucher, potentially reducing FDA review time and accelerating patient access to innovative therapies, thereby enhancing the company's competitive position in the market.
See More
Medicus Pharma Submits IND Application for Teverelix Trial in UAE
- IND Application Submitted: Medicus Pharma has submitted an Investigational New Drug application to the Abu Dhabi Department of Health for the Phase 2a PRECISION-E2 trial, aimed at evaluating Teverelix for symptomatic endometriosis in women in the UAE, marking a significant advancement in the biotech sector.
- Clinical Trial Design: The PRECISION-E2 study will enroll approximately 84 participants and will utilize a randomized, placebo-controlled design to assess the pharmacodynamics, safety, and tolerability of Teverelix, providing crucial data for future Phase 2b development.
- Treatment Regimen Exploration: The trial will test three different administration regimens for Teverelix, including subcutaneous and intramuscular injections, aiming to identify the optimal dose and method for effective estradiol suppression while maintaining a favorable safety profile, which could significantly enhance patients' quality of life.
- Precision Medicine Strategy: Medicus Pharma is incorporating the Emirati Genome Program to analyze genomic and phenotypic factors affecting treatment response and disease biology, striving to develop a comprehensive precision medicine strategy for endometriosis patients, thereby driving innovation in this field.
See More
Medicus Pharma Submits IND Application for Teverelix®
- Clinical Trial Innovation: Medicus Pharma has submitted an IND application for Teverelix®, aiming to conduct the first genomics-enabled Phase 2a clinical trial in the UAE, which seeks to integrate clinical outcomes and genomic analyses to optimize treatment options, potentially offering more personalized care for millions of women.
- Participant Recruitment Plan: The trial is expected to enroll approximately 84 participants, leveraging data from the Emirati Genome Program to explore how genetic variations may influence hormonal therapy responses, which could provide critical data support for future precision medicine initiatives.
- Multiple Dosing Regimen Evaluation: The study will assess three Teverelix® dosing regimens, including subcutaneous and intramuscular administration, with the objective of identifying the optimal dose and route to achieve effective estradiol suppression while maintaining a favorable safety profile, potentially transforming current treatment paradigms.
- Potential in Women's Health: Successful completion of this trial could lay the groundwork for future Phase 2b development, potentially extending to other women's health indications such as uterine fibroids, further advancing the application of precision medicine in estrogen-driven diseases.
See More
Medicus Pharma Submits Clinical Trial Application for Teverelix®
- Successful Trial Application: Medicus Pharma has successfully submitted a substantial modification application for Teverelix® through the European Clinical Trials Information System, marking a significant milestone in advancing its prostate cancer treatment strategy and facilitating the drug's registration development.
- Focus on High-Risk Patients: The study aims to address advanced prostate cancer patients with elevated cardiovascular risk, as Medicus believes Teverelix®'s unique pharmacologic profile may offer significant therapeutic advantages, thereby filling a critical treatment gap in the market.
- Significant Market Opportunity: Medicus estimates that advanced prostate cancer patients with elevated cardiovascular risk represent an approximately $4 billion annual market opportunity across major pharmaceutical markets, and successfully developing such a therapy could yield substantial long-term commercial value for the company.
- Future Development Plans: The company intends to initiate patient enrollment later this year, with data from the Phase 2b study expected to inform dose selection and registrational study design, further enhancing interactions with regulatory authorities in both Europe and the United States.
See More
Medicus Pharma to Participate in 2026 Bio International Conference
- Clinical Progress Update: Medicus Pharma will showcase clinical data for SkinJect® at the 2026 Bio International Conference, particularly highlighting a 55% histological clearance and 64% clinical clearance rate from the SKNJCT-003 study, indicating the therapy's potential in treating basal cell carcinoma and possibly opening new market opportunities for the company.
- FDA Interaction Progress: The company is actively engaging with the U.S. FDA in preparation for the SKNJCT-003 End-of-Phase 2 meeting and is applying for Rare Pediatric Disease and Orphan Drug Designations, which, if granted, could provide market exclusivity and expedited review benefits for SkinJect®.
- New Study Launch: The PRECISION-E2 Phase 2a clinical trial for Teverelix® has been initiated in the UAE, aimed at optimizing treatment options for endometriosis patients through genomic profiling, potentially establishing a new framework for precision medicine in women's health.
- Strategic Partnership Opportunities: Medicus focuses on de-risking through Phase 2 trials to generate decision-grade data that attracts pharmaceutical partners, enhancing the company's competitiveness and appeal in the biotechnology sector.
See More
Medicus Pharma Submits Rare Pediatric Disease Designation for SkinJect
- Regulatory Submission: Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect, targeting basal cell carcinoma treatment in Gorlin Syndrome patients, indicating the company's strategic focus on addressing significant unmet medical needs.
- Clinical Trial Results: The recent Phase 2 study of SkinJect demonstrated a 64% clinical clearance rate and a 55% histological clearance rate, showcasing its efficacy in treating basal cell carcinoma while maintaining a favorable safety and tolerability profile.
- Market Potential: Gorlin Syndrome affects an estimated 6,000 to 12,000 individuals in the U.S., and Medicus Pharma anticipates that the RPDD submission will bolster its regulatory strategy and facilitate the development of non-surgical treatment options.
- Stock Price Reaction: Medicus shares closed at $0.32, down 5.24%, reflecting market caution regarding the progress of its drug development, which may impact future funding and investor confidence.
See More
Medicus Pharma Submits Rare Pediatric Disease Application
- Rare Disease Application: Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect®, aimed at providing new treatment options for patients with Gorlin Syndrome, marking a significant milestone in advancing SkinJect® through the regulatory process.
- Clinical Trial Results: The recently completed Phase 2 study showed that the 200ug D-MNA treatment arm of SkinJect® achieved a 64% clinical clearance rate and a 55% complete response rate, indicating its potential as an important non-surgical treatment option for basal cell carcinoma.
- Market Opportunity: Gorlin Syndrome affects approximately 1 in 30,000 to 1 in 60,000 individuals globally, with an estimated U.S. patient population of 6,000 to 12,000, positioning SkinJect® to address this significant unmet medical need and tap into a market opportunity of around $2 billion.
- Regulatory Strategy: If granted Rare Pediatric Disease Designation, SkinJect® may qualify for a Priority Review Voucher, potentially reducing FDA review time and accelerating patient access to innovative therapies, thereby enhancing the company's competitive position in the market.
See More
Medicus Pharma Submits IND Application for Teverelix Trial in UAE
- IND Application Submitted: Medicus Pharma has submitted an Investigational New Drug application to the Abu Dhabi Department of Health for the Phase 2a PRECISION-E2 trial, aimed at evaluating Teverelix for symptomatic endometriosis in women in the UAE, marking a significant advancement in the biotech sector.
- Clinical Trial Design: The PRECISION-E2 study will enroll approximately 84 participants and will utilize a randomized, placebo-controlled design to assess the pharmacodynamics, safety, and tolerability of Teverelix, providing crucial data for future Phase 2b development.
- Treatment Regimen Exploration: The trial will test three different administration regimens for Teverelix, including subcutaneous and intramuscular injections, aiming to identify the optimal dose and method for effective estradiol suppression while maintaining a favorable safety profile, which could significantly enhance patients' quality of life.
- Precision Medicine Strategy: Medicus Pharma is incorporating the Emirati Genome Program to analyze genomic and phenotypic factors affecting treatment response and disease biology, striving to develop a comprehensive precision medicine strategy for endometriosis patients, thereby driving innovation in this field.
See More
Medicus Pharma Submits IND Application for Teverelix®
- Clinical Trial Innovation: Medicus Pharma has submitted an IND application for Teverelix®, aiming to conduct the first genomics-enabled Phase 2a clinical trial in the UAE, which seeks to integrate clinical outcomes and genomic analyses to optimize treatment options, potentially offering more personalized care for millions of women.
- Participant Recruitment Plan: The trial is expected to enroll approximately 84 participants, leveraging data from the Emirati Genome Program to explore how genetic variations may influence hormonal therapy responses, which could provide critical data support for future precision medicine initiatives.
- Multiple Dosing Regimen Evaluation: The study will assess three Teverelix® dosing regimens, including subcutaneous and intramuscular administration, with the objective of identifying the optimal dose and route to achieve effective estradiol suppression while maintaining a favorable safety profile, potentially transforming current treatment paradigms.
- Potential in Women's Health: Successful completion of this trial could lay the groundwork for future Phase 2b development, potentially extending to other women's health indications such as uterine fibroids, further advancing the application of precision medicine in estrogen-driven diseases.
See More
Medicus Pharma Submits Clinical Trial Application for Teverelix®
- Successful Trial Application: Medicus Pharma has successfully submitted a substantial modification application for Teverelix® through the European Clinical Trials Information System, marking a significant milestone in advancing its prostate cancer treatment strategy and facilitating the drug's registration development.
- Focus on High-Risk Patients: The study aims to address advanced prostate cancer patients with elevated cardiovascular risk, as Medicus believes Teverelix®'s unique pharmacologic profile may offer significant therapeutic advantages, thereby filling a critical treatment gap in the market.
- Significant Market Opportunity: Medicus estimates that advanced prostate cancer patients with elevated cardiovascular risk represent an approximately $4 billion annual market opportunity across major pharmaceutical markets, and successfully developing such a therapy could yield substantial long-term commercial value for the company.
- Future Development Plans: The company intends to initiate patient enrollment later this year, with data from the Phase 2b study expected to inform dose selection and registrational study design, further enhancing interactions with regulatory authorities in both Europe and the United States.
See More
